Home About Us Pipeline News Investors Contacts Careers

STOCK INFORMATION

UPCOMING EVENTS

There are no scheduled events at this time. Please check back later.

FEATURED PRESS RELEASE

  • 12/11/17 5:45 am PST

    Patent Claims for Extended Adjuvant Treatment Upheld

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the European Patent Office has upheld the claims in Puma's licensed European patent (EP 2416774), which were being opposed by Hexal AG. The intellectual property portfolio that was licensed from Pfizer in 2011 when Puma licensed neratinib included patents in a number of countries including Europe (EP 2416774) relating to methods of use ofmore...

SEARCH INVESTOR RELATIONS

CONTACTS

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

ir@pumabiotechnology.com